An FDA warning letter is a letter FDA sends, and usually posts publicly, when it believes a company has violated federal drug law; the GLP-1 telehealth letters cite misbranding through false or misleading labeling and advertising [3].
The letter waves, by date
| Letter date | Posted or announced | Who received letters | How many | Source |
|---|---|---|---|---|
| Dec 10, 2024 | Posted Dec 17, 2024 | Research-peptide sellers: Xcel Peptides, Swisschems, Summit Research Peptides, Prime Peptides; plus Veronvy for oral GLP-1 products, one claiming FDA approval | 4, plus Veronvy | [7] |
| Feb 26, 2025 | On fda.gov | USApeptide.com, a research-peptide seller | 1 | [8] |
| Sep 9, 2025 | Sep 2025 | Telehealth firms, compounders and drugmakers, including Hims, Hers, Remedy Meds, DirectMeds, Fancy Meds, Novo Nordisk and Eli Lilly | Disputed: more than 50, 67 or about 80, depending on the source | [1][4][9][5] |
| Feb 20, 2026 | Announced Mar 3, 2026 | Telehealth companies, after FDA reviewed their websites in December 2025 | 30 | [1][10] |
| Mar 31, 2026 | Posted Apr 7, 2026 | Research-peptide sellers, including Prime Sciences and Mile High Compounds | 2 opened on fda.gov; a third-party list adds Pink Pony Peptides and Gram Peptides | [11][9] |
| Jun 8, 2026 | Posted Jun 16, 2026 | Telehealth companies, under the subject 'False & Misleading Claims/Misbranded (Telehealth)' | 25 | [2][5] |
| Aug 24, 2026 | Posted Sep 1, 2026 | Research-peptide sellers: Peak Performance Peptides, Royal Peptides, Peptide Partners, NuScience Peptides, Tex Peptides | 5 | [12] |
| Sep 18, 2026 | Posted Sep 22, 2026 | Empower Pharmacy, a large 503A compounding pharmacy, after an inspection | 1 | [6] |
Where the counts conflict
FDA did not publish a GLP-1-only count for the September 2025 letters in the sources we reviewed. FDA described sending thousands of letters to drug and telehealth companies over six months, covering all drug advertising [1]. The Rx Index counts more than 50 letters, mostly dated Sep 9, 2025 [4]. WeightLossRankings.org counts 67 GLP-1-related letters dated September 2025, including drugmakers, foreign ingredient makers and duplicates [9]. Sheppard Mullin, a law firm, cites about 80 warning letters plus 40 untitled letters [5].
The February 2026 letters also carry two dates. The letters on fda.gov are dated Feb 20, 2026 [10], while the National Law Review lists Mar 3, 2026, the day FDA announced them [13]. We use the letter date. Separately, on Feb 6, 2026, FDA announced it intends to act against GLP-1 ingredients used in non-FDA-approved compounded drugs, named Hims & Hers, and warned of seizure and injunction without further notice [14].
What the letters cite
- 'Same active ingredient' claims. Phrases like 'same active ingredient as Ozempic and Wegovy' appear in letters to Hims, Hers, Remedy Meds, Fancy Meds and DirectMeds in 2025 and to MEDVi and SkinnyRx in 2026. FDA says the wording implies the compounded products are the same as, or were evaluated like, FDA-approved drugs [15].
- The telehealth brand on the vial label. FDA says a telehealth company's name on a compounded drug label implies that company is the compounder, citing 21 CFR 201.1(h)(2). This was cited to MEDVi, Ivim, SkinnyRx, Eden and OrderlyMeds [16].
- 'FDA-licensed' or 'FDA-approved' pharmacy claims. Cited to OrderlyMeds, Eden and Maximus [17]. FDA says it does not approve or license any pharmacy or outsourcing facility [18].
- 'Generic', 'FDA-approved' and 'clinically proven' claims. Phrases quoted from the 2026 letters include 'Generic Zepbound' and 'This FDA-approved treatment promotes safe, effective weight loss' [13].
- Research use only labels. Letters to peptide sellers found that products labeled for research were sold for human use, making them unapproved new drugs [19]. Some used code names such as 'GLP-3 RT' for retatrutide, and FDA treated bacteriostatic water sold with peptides as a drug [11].
- Compounding pharmacy problems. The Empower letter called tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) 'essentially copies' of approved drugs, said significant-difference notes were missing or repeated word for word, and cited insanitary conditions and manufacturing-quality failures [6].
Most telehealth letters rest on misbranding under sections 502(a) and 502(bb) of the Food, Drug, and Cosmetic Act, which cover false or misleading labeling and advertising of compounded drugs [3]. For the rules behind these claims, see compounded semaglutide, compounded tirzepatide and research-use-only GLP-1s.
What a letter means, and what it does not
- A letter is FDA's written position that a company broke federal drug law, with the specific claims or conditions it found. It is not a court ruling.
- Most telehealth letters are about words: what a website, ad or vial label says. They do not report lab testing of the drug inside the vial. The Empower letter is different, because it followed an inspection of the pharmacy [6].
- A fixed claim is not the same as no record. On Oct 17, 2026, neither phrase FDA cited appeared on hims.com/weight-loss [20], and Remedy Meds' cited phrase was not on its home page [21]. The letter stays on the record.
- No letter is not a clean bill of health. Compounded GLP-1s are not FDA-approved whether or not the seller got a letter, and several companies we rate Avoid have no FDA letter at all.
How we use letters in our verdicts
Our rating rules are set out in our editorial standards. A warning letter whose cited claims are still live on the company's site or labels puts a provider at Avoid. A past letter whose cited claims have been fixed, with an otherwise reasonable record, puts it at Caution. A provider can also land at Avoid without any letter, for a BBB rating of D or F, a pattern of billing or refund complaints, or action by a regulator or against its pharmacy. Each review states the date we last checked the cited claims.
Consumer brands with GLP-1 warning letters
| Brand | Letter date | What FDA cited | Our review | FDA letter |
|---|---|---|---|---|
| Hims (Hims & Hers Health) | Sep 9, 2025 | 'Same active ingredient as Ozempic and Wegovy'; 'clinically proven ingredients' | Hims & Hers weight loss review | Read on fda.gov |
| Hers (Hims & Hers Health) | Sep 9, 2025 | 'Same active ingredient as Ozempic and Wegovy'; 'clinically proven ingredients' | Hers weight loss review | Read on fda.gov |
| Remedy Meds | Sep 9, 2025 | 'Same active ingredient' as Ozempic, Wegovy, Mounjaro and Zepbound | Remedy Meds review | Read on fda.gov |
| DirectMeds | Sep 9, 2025 | 'Same active ingredient as the brand-name drug' | Direct Meds review | Read on fda.gov |
| Fancy Meds | Sep 9, 2025 | 'Same active ingredient' claims; FDA-monitored pharmacy and FDA-approved ingredient language | No review yet | Read on fda.gov |
| MEDVi | Feb 20, 2026 | 'Same active ingredient' claims; MEDVi name on vial labels | MedVi review | Read on fda.gov |
| Ivim | Feb 20, 2026 | Ivim name on compounded product labels | IVIM Health review | Read on fda.gov |
| SkinnyRx (Lean Rx) | Feb 20, 2026 | SkinnyRx name on labels; 'same active ingredient' claims | SkinnyRx review | Read on fda.gov |
| Eden | Jun 8, 2026 | Eden name on labels; 'FDA-licensed 503(a) outsourcing facilities' | Eden review | Read on fda.gov |
| OrderlyMeds | Jun 8, 2026 | OrderlyMeds logo on labels; 'FDA-licensed pharmacy' | OrderlyMeds review | Read on fda.gov |
| Maximus | Jun 8, 2026 | 'Clinically studied ingredients'; 'proven to lose weight effectively'; 'FDA approved pharmacies' | Maximus review | Read on fda.gov |
Hims & Hers later agreed with Novo Nordisk, in an announcement on Mar 9, 2026, to offer branded Ozempic and Wegovy and stop most marketing of compounded GLP-1s [22]. We rate it Avoid for a separate reason: a July 2026 lawsuit from the FTC, Utah and Los Angeles County over subscriptions, cancellation and health data sharing [23].
Brands we checked with no letter found
As of Oct 17, 2026, we found no FDA warning letter to Ro, Mochi Health, Henry Meds, Noom, LifeMD, Shed (ShedRx), Fridays, Embody, bmiMD, Found, Willow, Hone Health, Valhalla Vitality, PeterMD, DudeMeds or TrimRx, after searching fda.gov and a 163-letter compilation [9]. Some of these still rate Avoid for other reasons: see our reviews of Fridays, Shed, TrimRx and Mochi Health. For providers that pass our checks, see best online GLP-1 programs.
Every GLP-1 letter we have logged
The table lists each letter's date, the company, what FDA cited and a link to the letter on fda.gov. Where we have not opened a letter ourselves, the table says so.
| Company | Letter date | What FDA cited | Status now |
|---|---|---|---|
| Empower Clinic Services, LLC dba Empower Pharmacy | Sep 18, 2026 Read the letter | Tirzepatide/niacinamide and semaglutide/cyanocobalamin are 'essentially copies'; missing or templated significant-difference determinations; insanitary conditions; CGMP; unapproved new drugs; 502(f)(1) | 503A compounder (inspection), not a marketing letter. Posted 2026-09-22. |
| Peptide Partners LLC | Aug 24, 2026 Read the letter | Unapproved new drugs: semaglutide, tirzepatide, retatrutide ('GLP-3 Reta'), SS-31, tesamorelin, PT-141, BAC water; 'for research use only' rejected | Posted 2026-09-01. |
| Royal Peptides LLC | Aug 24, 2026 Read the letter | Tirzepatide, semaglutide, retatrutide and others (per Spakinect) | Not opened (rate limited). |
| Peak Performance Peptides | Aug 24, 2026 Read the letter | Retatrutide, semaglutide and others (per Spakinect) | Not opened. |
| NuScience Peptides LLC | Aug 24, 2026 Read the letter | Tirzepatide, semaglutide, retatrutide, survodutide, mazdutide and others (per Spakinect) | URL from VialAudit link list; not opened. |
| TXP Innovations LLC dba Tex Peptides | Aug 24, 2026 Read the letter | Semaglutide, tirzepatide, retatrutide and others (per Spakinect) | URL from VialAudit link list; not opened. |
| Wholesale Peptide | Jun 17, 2026 Read the letter | Unapproved new drugs: Prostamax, gonadorelin; 'RESEARCH USE ONLY' labeling contradicted | No GLP-1 products cited; included for RUO precedent. |
| Eden Health International Inc. dba Eden | Jun 8, 2026 Read the letter | 'Eden' on labels; 'FDA-licensed 503(a) outsourcing facilities' | Watchlist: Eden. Jun 2026 wave, posted 2026-06-16. |
| OrderlyMeds LLC dba OrderlyMeds | Jun 8, 2026 Read the letter | OrderlyMeds logo on labels; 'FDA-licensed pharmacy' | Watchlist: Orderly. Jun 2026 wave, posted 2026-06-16. |
| Maximus Health, Inc. dba Maximus | Jun 8, 2026 Read the letter | 'Clinically studied ingredients'; 'Proven to lose weight effectively'; 'FDA approved pharmacies' (maximustribe.com) | Watchlist: Maximus. Jun 2026 wave, posted 2026-06-16. |
| Altru Telehealth, LLC dba Altru Telehealth | Jun 8, 2026 Read the letter | 'FDA approved active ingredient'; 'same results'; 'FDA approved' pharmacy (per Spakinect) | Jun 2026 wave. |
| Momentum Health 360 dba Momentum Health | Jun 8, 2026 Read the letter | Momentum Health on labels; comparisons to Ozempic, Wegovy, Mounjaro, Zepbound (per Spakinect) | Jun 2026 wave. |
| Ready Med | Jun 8, 2026 Read the letter | Ready Med on labels; 'same active ingredient' as Mounjaro, Zepbound, Ozempic, Rybelsus (per Spakinect) | Jun 2026 wave. |
| D&H Medical Services | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Public Health Solution LLC dba DrMedHealth | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| FITISH | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Nexlife Inc. dba Nexlife | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| VivioMD Group LLC dba VivioMD | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Trinity HealthCare Supply, LLC dba altRx | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Medica Weight Loss | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Roen Health, Inc. dba RoenRx | Jun 8, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Jun 2026 wave (posted 2026-06-16) |
| Prime Sciences | Mar 31, 2026 Read the letter | Unapproved new drugs: cagrilintide, 'GLP1-R' (retatrutide), 'GLP1-S', 'GLP1-T', mazdutide, BAC water kit; 'laboratory research purposes only' rejected | Posted 2026-04-07. |
| Mile High Compounds LLC | Mar 31, 2026 Read the letter | Unapproved new drugs: 'GLP-1 SM', 'GLP-2 TRZ', 'GLP-3 RT' (retatrutide), BAC water; forum dosing chart up to 12 mg retatrutide | Posted 2026-04-07. |
| MEDVi, LLC dba MEDVi | Feb 20, 2026 Read the letter | 'Same active ingredient as Wegovy and Ozempic'; 'Same active ingredient as Mounjaro and Zepbound'; MEDVi name on vial labels implies it is the compounder | Watchlist: MedVi. Mar 2026 wave (announced 2026-03-03). |
| Ivim Services LLC dba Ivim | Feb 20, 2026 Read the letter | 'Ivim' on compounded product labels implies Ivim is the compounder (21 CFR 201.1(h)(2)); other site claims to be addressed | Watchlist: IVIM. Mar 2026 wave. |
| Lean Rx, Inc. dba SkinnyRx | Feb 20, 2026 Read the letter | SkinnyRx on labels; 'same active ingredient as name-brand GLP-1 medications'; 'contains the same active ingredient as FDA-approved medications' | Watchlist: SkinnyRx. Mar 2026 wave. |
| Join Josie | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| 24HrDoc, Inc. dba 24HrDoc | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Belle Health LLC dba Belle | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Premium Health Management Inc. dba Premium Health | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Dripgym Mobile Parent, LLC dba Amp Health | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Viv Health, Inc. dba VIV RX | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Kare Solutions, LLC dba Zappy | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| BluefitMD | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Levity Inc. dba Levity | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| FitRX, LLC dba FitRx | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| MaxLife Technologies Inc. dba Maxlife | Feb 20, 2026 Read the letter | Not opened; listed on fda.gov search results with this title and date | Mar 2026 wave (announced 2026-03-03) |
| Hims & Hers Health, Inc. dba Hims | Sep 9, 2025 Read the letter | 'Same active ingredient as Ozempic and Wegovy'; 'Clinically proven ingredients' (compounded semaglutide); 502(a), 502(bb) | Watchlist: Hims & Hers. Sep 2025 wave. |
| Hims & Hers Health, Inc. dba Hers | Sep 9, 2025 Read the letter | 'Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy'; 'Clinically proven ingredients' (forhers.com) | Watchlist: Hims & Hers. Sep 2025 wave. |
| Remedy Meds | Sep 9, 2025 Read the letter | 'Same active ingredient as Ozempic and Wegovy'; 'Same active ingredient as Mounjaro and Zepbound' | Watchlist. Sep 2025 wave. |
| directmeds.com, Inc. dba DirectMeds | Sep 9, 2025 Read the letter | 'Compounded semaglutide contains the same active ingredient as branded semaglutide'; 'use the same active ingredient as the brand-name drug' | Watchlist: Direct Meds. Sep 2025 wave. |
| Fancy Meds, LLC dba Fancy Meds | Sep 9, 2025 Read the letter | 'Same active ingredient as Ozempic and Wegovy' / 'Mounjaro and Zepbound'; FDA-monitored pharmacy and FDA-approved ingredients language | Watchlist: FancyMeds. Sep 2025 wave. |
| GLP-1 Solution | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave. |
| JulyMD | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Vitals RX | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| SemaBio | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| GenLabMeds | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| iVisitDoc, Inc. dba iVisitDoc | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Curex | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| inspire.clinic | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| TRYM Health, Inc. dba TRYM Health | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Lumimeds | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| SimpleRx | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| ASN-LABS | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| ybycmeds | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Healthy Male | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Amazing Meds | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Expert Aesthetics | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Healthon Inc. dba Healthon | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Get.Fit.Medical, LLC dba Get.Fit.Medical | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Master Pharmaceuticals Group | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| The HCG Institute | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave |
| Eli Lilly and Company | Sep 9, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Sep 2025 wave. Brand manufacturer DTC-ad letter, not compounding. |
| USApeptide.com | Feb 26, 2025 Read the letter | Not opened; listed on fda.gov search results with this title and date | Research-peptide seller. |
| Summit Research Peptides | Dec 10, 2024 Read the letter | Unapproved new drugs (505(a), 301(d)): semaglutide, retatrutide, cagrilintide, tirzepatide, mazdutide labeled 'RESEARCH USE ONLY' | Research-peptide seller. Posted 2024-12-17. |
| Xcel Research LLC (Xcel Peptides) | Dec 10, 2024 Read the letter | Unapproved GLP-1s incl. semaglutide/tirzepatide/retatrutide (per FDA roundup) | Research-peptide seller. Not opened. |
| Swisschems | Dec 10, 2024 Read the letter | Unapproved GLP-1s (per FDA roundup) | Research-peptide seller. Not opened. |
| Prime Vitality, Inc. dba Prime Peptides | Dec 10, 2024 Read the letter | Unapproved GLP-1s (per FDA roundup) | Research-peptide seller. Not opened. |
If you bought from a company with a letter
A letter about marketing does not by itself mean your medicine is unsafe. Ask the company which pharmacy made your drug and check that its name is on the label. Follow your prescriber's instructions and the pharmacy label, and tell your prescriber about any side effects.
Questions people ask
How many FDA warning letters have gone to GLP-1 telehealth companies?
Why is FDA sending warning letters to GLP-1 telehealth companies?
Did Hims & Hers get an FDA warning letter?
Does an FDA warning letter mean the medicine is unsafe?
Not by itself. Most telehealth letters cite marketing and label claims, not lab results. The Sep 18, 2026 letter to Empower Pharmacy is an exception: it followed an inspection and cites insanitary conditions and manufacturing-quality failures [6].
Is compounded semaglutide or tirzepatide still legal?
Only in narrow cases. FDA says 503A pharmacies may compound for an individual patient, and copies of approved drugs are barred unless the prescriber documents a significant difference for that patient. 503B outsourcing facilities may not compound either drug from bulk ingredients [25].
Which telehealth companies have no FDA warning letter?
As of Oct 17, 2026, we found none for Ro, Mochi Health, Henry Meds, Noom, LifeMD, Shed, Fridays, Embody, bmiMD, Found, Willow, Hone Health, Valhalla Vitality, PeterMD, DudeMeds or TrimRx [9]. No letter does not mean a clean record.
How does an FDA letter affect a Wellchosen Health rating?
A letter whose cited claims are still live puts a provider at Avoid; a past letter with the claims fixed and an otherwise reasonable record puts it at Caution. For example, Remedy Meds got a letter dated Sep 9, 2025, and its cited phrase was not on its home page on Oct 17, 2026 [21], so we rate it Caution. The full rules are in our editorial standards.
Sources
25 cited
- FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. US Food and Drug Administration, Mar 3, 2026.
- FDA warning letters on compounded GLP-1 telehealth marketing. Spakinect, Jun 18, 2026.
- Warning letter: Remedy Meds. US Food and Drug Administration, Sep 9, 2025.
- Compounded GLP-1 enforcement tracker. The Rx Index, Sep 3, 2026.
- FDA's focus returns to compounding and telehealth: another wave of warning letters. Sheppard Mullin, Jun 18, 2026.
- Warning letter: Empower Clinic Services, LLC dba Empower Pharmacy. US Food and Drug Administration, Sep 18, 2026.
- FDA Roundup: December 17, 2024. US Food and Drug Administration, Dec 17, 2024.
- Warning letter: USApeptide.com. US Food and Drug Administration, Feb 26, 2025.
- FDA warning letters compilation. WeightLossRankings.org, Sep 30, 2026.
- FDA ramps up crackdown on GLP-1 drug compounders with fresh batch of 30 warning letters. Fierce Pharma, Mar 4, 2026.
- Warning letter: Mile High Compounds LLC. US Food and Drug Administration, Mar 31, 2026.
- FDA warning letters to peptide GLP-1 sellers. Spakinect, Sep 15, 2026.
- GLP-1 compliance: FDA targets telehealth marketing with 30 new warning letters. National Law Review, Mar 12, 2026.
- FDA intends to take action against non-FDA-approved GLP-1 drugs. US Food and Drug Administration, Feb 6, 2026.
- Warning letter: MEDVi, LLC dba MEDVi. US Food and Drug Administration, Feb 20, 2026.
- Warning letter: Ivim Services LLC dba Ivim. US Food and Drug Administration, Feb 20, 2026.
- Warning letter: OrderlyMeds LLC dba OrderlyMeds. US Food and Drug Administration, Jun 8, 2026.
- FDA: what telehealth companies should know when promoting compounded drugs. US Food and Drug Administration, Jun 15, 2026.
- Warning letter: Summit Research Peptides. US Food and Drug Administration, Dec 10, 2024.
- Hims weight loss pricing. Hims & Hers Health, Oct 17, 2026.
- Remedy Meds home page. Remedy Meds, Oct 17, 2026.
- FDA warning letters, Hims and Novo Nordisk: compounded GLP-1s. Frier Levitt, Mar 9, 2026.
- FTC, Utah and Los Angeles County sue Hims & Hers. Insurance Journal, Jul 30, 2026.
- Warning letter: Hims & Hers Health, Inc. dba Hims. US Food and Drug Administration, Sep 9, 2025.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. US Food and Drug Administration, Apr 1, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.